Plant Name: Trichosanthes kirilowii
Taxonomic Information:
Plant ID: NPO21707
Plant Latin Name: Trichosanthes kirilowii
Taxonomy Genus: Trichosanthes
Taxonomy Family: Cucurbitaceae
Plant External Links:
NCBI TaxonomyDB:
3677
Plant-of-the-World-Online:
294222-1
Used in Medicines:
Country/Region:
South Korea; Vietnam; ChinaTraditional Medicine System:
TCM; KampoMedicinal Functions:
Abortifacient; Antibiotic; Anticholesterolemic; Antifungal; Antiinflammatory; Antitussive; Cancer; Depurative; Emollient; Expectorant; Febrifuge; Galactogogue; Laxative; Oxytoxic; Sialagogue; Skin; Uterine tonic; Vulnerary
Geographical Distribution:
Japan; South Korea; Vietnam; China; South Africa
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA3; ADORA2A; ADORA1; FFAR4; FFAR1; | |
| ACHE; | |
| BLM; ADK; HSD17B1; ALOX15; NOX4; | |
| GABRR1; | |
| FLT3; CSNK2A1; | |
| CA12; CA7; CA4; | |
| ESR2; | |
| MMP12; | |
| HIF1A; TP53; | |
| KMT2A; | |
| LMNA; FABP3; FABP4; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.862E-09 | 2.144E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.704E-08 | 6.829E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.304E-07 | 1.578E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.123E-07 | 3.401E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.457E-07 | 4.622E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.057E-06 | 8.127E-04 | ADORA1, ADORA2A, ADORA3, CYP1B1, FABP3, KMT2A, LMNA, NOX4, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.681E-06 | 1.046E-03 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.748E-06 | 1.057E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.048E-06 | 1.543E-03 | ADORA1, CYP1A1, HIF1A, LMNA, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 3.873E-06 | 1.874E-03 | ADORA1, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.881E-06 | 2.262E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.229E-06 | 2.372E-03 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.486E-06 | 2.769E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 7.471E-06 | 2.798E-03 | ADORA1, ADORA2A |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 8.206E-06 | 2.978E-03 | ACHE, ADORA1, ADORA2A, ALOX15, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FLT3, HIF1A, KMT2A, LMNA, THPO, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 9.031E-06 | 3.121E-03 | ACHE, ADORA3, ALOX15, CYP1A1, TP53 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.067E-05 | 3.573E-03 | FABP3, FABP4, FFAR4 |
| BP | GO:0065007; biological regulation | GO:0065009; regulation of molecular function | 1.451E-05 | 4.450E-03 | ADORA1, ADORA2A, ADORA3, BLM, CSNK2A1, CYP1B1, ESR2, FABP4, FFAR1, FLT3, HIF1A, KMT2A, NOX4, THPO, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.493E-05 | 4.477E-03 | CYP1A1, CYP1A2 |
| BP | GO:0040011; locomotion | GO:0030334; regulation of cell migration | 2.226E-05 | 5.584E-03 | ADORA1, ADORA3, CYP19A1, CYP1B1, HIF1A, LMNA, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.578E-05 | 6.194E-03 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.168E-05 | 7.482E-03 | BLM, CA12, CA4, CA7, ESR2, KMT2A, MMP12, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.313E-05 | 7.675E-03 | ADORA1, ADORA2A, CYP19A1, FFAR4 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 3.352E-05 | 7.683E-03 | ACHE, ADORA2A, FFAR1, HIF1A, MMP12 |
| BP | GO:0008152; metabolic process | GO:0001932; regulation of protein phosphorylation | 3.774E-05 | 8.386E-03 | ADORA1, ADORA2A, ALOX15, BLM, FABP4, FFAR4, FLT3, NOX4, THPO, TP53 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 4.593E-05 | 9.710E-03 | ADORA2A, CYP19A1, FFAR1, HIF1A |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.741E-05 | 9.926E-03 | CA12, CA4, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.758E-08 | 2.510E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.035E-06 | 4.707E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.204E-05 | 7.290E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 6.218E-05 | 1.132E-03 | GABRR1, ADORA2A, ADORA3, ADORA1, TSHR |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.259E-06 | 6.853E-05 | CA12, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 8.841E-05 | 1.341E-03 | FABP4, ADORA1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.510E-04 | 1.963E-03 | FLT3, TP53, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.949E-04 | 2.216E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.748E-04 | 2.779E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 8.376E-04 | 7.608E-03 | ADORA3, ADORA1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 9.197E-04 | 7.608E-03 | CYP1A2, ALOX15 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; TP53; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| NA: NA | GIST | NA | FLT3; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; ADORA2A; ADK; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; TP53; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; ADORA3; TP53; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
